CLAIM AMENDMENTS

1. (currently amended): A compound of ~~the general~~ formula I



I

or pharmaceutically acceptable ~~prodrugs,~~ salts~~, hydrates, solvates, crystal forms~~ or diastereomers thereof, wherein:

one carbon of ring B is substituted with Z and the rest of the carbons are independently substituted with Y;

A is a ring selected from:



where D is selected from H, C_{1-4} alkyl, halogen, amino;

W is:

(i) NR^1R^2 where R^1 and R^2 are independently H, C_{1-4} alkyl, C_{1-4} alkylCF_3, aryl, hetaryl, C_{1-4} alkylaryl, C_{1-4} alkylhetaryl, C_{3-8} cycloalkyl, C_{2-6} alkenyl, cyclohetalkyl, C_{1-4} alkylcycloalkyl, C_{1-4} alkyl cyclohetalkyl, or R^1 and R^2 are joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR^3; and R^3 is selected from H, C_{1-4} alkyl, aryl, hetaryl, C_{1-4} alkyl aryl, C_{1-4} alkyl hetaryl, COR^4 where R^4 is selected from H, C_{1-4} alkyl, aryl, hetaryl; or

(ii) H, C_{1-4} alkyl, aryl, hetaryl, C_{3-8} cycloalkyl, cyclohetalkyl, C_{1-4} alkylaryl, C_{1-4} alkylhetaryl, C_{3-8} cycloalkyl, C_{1-4} alkylcycloalkyl, C_{1-4} alkyl cyclohetalkyl;

Y is H, halogen, CN, CF_3, nitro, OH, C_{1-4} alkyl, C_{1-4} alkylNR^5R^6, C_{1-4} alkylhetaryl, OC_{1-4} alkyl, OC_{2-4} alkylOC_{1-4}alkyl, OC_{1-4} alkylNR^5R^6, OC_{1-4} alkylhetaryl, OC_{1-4} alkylcyclohetalkyl, SC_{1-4} alkyl, SC_{2-4} alkylOC_{1-4}alkyl, SC_{1-4} alkylNR^5R^6, NR^5R^6, NR^5COR^6, $NR^5SO_2R^6$; and R^5 and R^6 are each independently H, C_{1-4} alkyl, or may be joined to form an optionally substituted

3-6 membered ring optionally containing an atom selected from O, S, NR^7 and R^7 is selected from H, C_{1-4} alkyl, aryl, hetaryl, C_{1-4} alkylaryl, C_{1-4} alkylhetaryl;

Z is selected from:



where R^8 is selected from H, C_{1-4} alkyl;

R^9 and R^{10} are independently selected from H, C_{1-4} alkyl, C_{1-4} alkyl$NR^{12}R^{13}$, C_{1-4} alkylOR^{12}, C_{1-4} alkylhetaryl or may be joined to form a 5-8 membered ring containing an atom selected from SO, or SO_2;

R^{11} is selected from OH, OC_{1-4} alkyl, $NR^{12}R^{13}$;

n is 0-4;

where R^{12} and R^{13} are independently selected from H, C_{1-4} alkyl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR^{14}; and R^{14} is selected from H, C_{1-4} alkyl.

2. (previously presented): A compound according to claim 1 wherein Z is selected from:






wherein R^8, R^9, R^{10} and R^{11} and n are as defined in claim 1.

3. (currently amended): A compound selected from the group consisting of:









and

including the pharmaceutically acceptable salts or diastereomers thereof.

4. (previously presented): A compound according to claim 1, wherein the compound irreversibly inhibits JAK-3.

5. (previously presented): A compound according to claim 1, wherein the compound selectively inhibits JAK 3 with respect to JAK 1 or JAK 2.

6. (previously presented): A composition comprising a carrier and a compound according to claim 1.

7. (withdrawn): A method of treating a tyrosine kinase-associated disease state, the method comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition thereof.

8. (canceled)

9. (withdrawn): A method of suppressing the immune system of a subject, the method comprising administering a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition thereof.

10-13. (canceled)